Salazar-Vázquez JA, Lugo-García JA

Language: Spanish
References: 14
Page: 14-26
PDF size: 245.60 Kb.

ABSTRACT

Introduction. The bening prostatic hiperplasia (BPH) is a non cancerous growth of the prostatic gland binded the age, and the hormonal secretion. This is responsible above the main of urinary symptoms in most men, usually when shifting the 50-year-old. In patients with obstructive prostatic growth are treated by surgery, the intraoperative bleeding is one of the complications that present and difficult surgery, as well as complicate the postoperative. The finasteride is an enzyme inhibitor of 5 alpha reductase that blocks the conversion of testosterone to dihydrotestosterone and is licensed for the treatment of BPH. Objective. Determine the efficacy of finasteride to reduce intraoperative bleeding in patients with transurethral Foley catheter, for more than a month, treated by transurethral resection of prostate. Conclusions. The preoperative use of finasteride for a previous month to TURP was effective in reducing perioperative bleeding in patients with Foley catheter, and reduced the hospital stay after the surgical procedure in 90% of cases

REFERENCES

1. Lowe FC, McConnell JD, Hudson PB, et al. Long-term experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003; 61: 791-6.

2. John FD, Harbinder S, Raju A, Sirage N, David RT, Mike CF. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for drecreasing operative blood loss. J Urol 2002; 168: 2024-6.

3. Pareek G, Shevchuk M, Armenakas NA, et al. The effect of finasteride on the expression of vascular endothelial growth factor and micro-vessel density: A possible mechanism for decreased prostatic bleeding in treated patient. J Urol 2003; 169: 20-3.

4. Delakas D, Lianos E, Karyotis I, Cranidis A. Finasteride: A long-term follow-up in the treatment of recurrent hematuria associated with benign prostatic hyperplasia. Urol Int 2001; 67: 69-72. Saunders an imprint of Elselvier Science. Philadelphia.

5. Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of de prostate. Urology 2000; 55: 684.

6. Miller MI, Puchner PJ. Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term followup. Urology 1998; 51: 237.

7. Stoner E, Finasteride Study Group. The clinical effects of a 5 alfa reductase inhibitor, finasteride, on benign prostatic hyperplasia. J Urol 1992; 147: 1298.

8. Carlin BI, Bodner DR, Spirnak JP, Resnick MI. Role of finasteride in the treatment of recurrent hematuria secondary to benign prostatic hyperplasia. Prostate 1997; 31: 180.

9. Moon SY, Moon WC, Choi HR, Gi YJ. Finasteride inhibits angiogenesis and expression of VEGF in human BPH. J Urol 1998; (suppl. 159): 332 (Abstract 1276).

10. Foley SJ, et al. Hematuria and BPH: a prospective study on the effect of finasteride. Br J Urol 1999; 83: 4-6.

11. Walsh P, Retik A, et al. Campbell Urology. 8th Ed. Vol. 2. p. 1349-474.

12. Kirby R. Prostatic diseases. 3a. Ed. Chapter 5. Spain: The Parthenon Publishing Group; 2003, p. 23-9.

13. Bailey DM, Foley SJ, Wedderburn A. Effect of finasteride on microvessel density (MVD) in patients with recurrent hematuria related to prostatic hypertrophy (BPH). J Urol 1999; (Suppl. 161): 363 (Abstract 1406).

14. Marshall S, et al. Treatment of prostatic bleeding suppression of angiogenesis by androgen deprivation. J Urol 1993; 149: 1553-7.